The price of CYRX is predicted to go up -1.89%, based on the high correlation periods with KITT. The similarity of these two price pattern on the periods is 96.87%.
CYRX
KITT
Down: -1.89%Similarity: 96.87%
CYRX Revenue Forecast
CYRX EPS Forecast
CYRX FAQs
What is bull’s view on CYRX?
CYRX stock is currently trading at $7.94, and the bull's view is optimistic due to the launch of the Cryoport Express Cryogenic HV3 Shipping System, which enhances efficiency and accessibility for biologics transport. Analysts like Needham have reiterated a "Strong Buy" rating with a price target of $11, reflecting a 37% upside potential. The innovative product launch and growth in advanced therapies logistics support the bullish sentiment.
What is bear's view on CYRX?
CYRX stock, currently trading at $7.94, faces bearish sentiment due to insider selling and mixed financial performance, including revenue misses in Q3 2024. Analysts maintain a cautious "Hold" rating, citing challenges in the MVE segment and broader market uncertainties. Despite recent innovations like the HV3 shipping system, the stock struggles to gain momentum amidst these headwinds.
What is CYRX revenue forecast for next quarter?
The market consensus for CYRX's revenue in the upcoming quarter is projected to be approximately $58.84M USD.
What is CYRX eps forecast for next quarter?
The market consensus for CYRX's eps in the upcoming quarter is projected to be approximately $0.27 USD.
UBS raised the firm's price target on Cryoport to $9 from $7 and keeps a Neutral rating on the shares. While the firm is optimistic about the long-term growth prospects of the company's services business, UBS believes MVE sales are likely to pressure near-term forecasts, the analyst tells investors in a research note. The firm says its recent site visit highlighted inherent synergies between CryoPort's acquisitions and increased its conviction in CryoPort's ability to capitalize on momentum in cell and gene therapy, but the firm continues to expect near-term pressure on product sales and sponsor investment.